about
CD164 monoclonal antibodies that block hemopoietic progenitor cell adhesion and proliferation interact with the first mucin domain of the CD164 receptorNovel mesenchymal and haematopoietic cell isoforms of the SHP-2 docking receptor, PZR: identification, molecular cloning and effects on cell migrationOsteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells.Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches.Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer.Microarray expression analysis of genes and pathways involved in growth plate cartilage injury responses and bony repair.SAMSN1 is a tumor suppressor gene in multiple myeloma.Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survivalTWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis.BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cellsBone Marrow Recovery by Morphometry during Induction Chemotherapy for Acute Lymphoblastic Leukemia in Children.Twist-1 induces Ezh2 recruitment regulating histone methylation along the Ink4A/Arf locus in mesenchymal stem cells.Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.The role of the chemokine CXCL12 in osteoclastogenesis.Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance.Identification of Novel EZH2 Targets Regulating Osteogenic Differentiation in Mesenchymal Stem CellsConcise review: mesenchymal stromal cells: potential for cardiovascular repair.A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis.A role for pericytes as microenvironmental regulators of human skin tissue regeneration.Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment.Genomic profiling of mesenchymal stem cells.Dysregulation of bone remodeling by imatinib mesylate.Potential applications for using stem cells in spine surgery.Intramyocardial navigation and mapping for stem cell delivery.The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.Optimization of the cardiovascular therapeutic properties of mesenchymal stromal/stem cells-taking the next step.Current and future applications for stem cell therapies in spine surgery.Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.Brief report: the differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation.hTERT transcription is repressed by Cbfa1 in human mesenchymal stem cell populations.Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE).The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro.
P50
Q22254444-3501927A-3EE6-41C8-A581-6C878A0D3BDEQ24535532-EF007374-8759-4C87-BABF-847599B65523Q27316833-FDF6D4D7-89C6-42ED-8497-BBA25CF0C6CCQ31144457-0E1E9E99-8EE9-4D23-BFF4-1B92DC08C06FQ33555818-C5482BE3-F441-4826-9BA8-4CA6455DF183Q33558170-1DF71277-32A4-4441-891E-89DF23713F35Q33829094-25F600BD-A870-4B79-8562-FA5D2ACC41A9Q33882079-0262EA6A-991F-4A76-A37F-8F037094A8CFQ34183757-244435A0-CD09-4FB3-9E21-F96633376A51Q34347229-61E1120D-48AC-48EC-B9D1-B9948B036890Q34556156-403A56AE-7ECF-4BF0-98D8-6E51860A813BQ34633876-D5A1B6A0-4949-48AF-9554-365B629B9A4CQ35092962-74C48AFA-683A-496C-A641-397AB95B1B5CQ35574955-474841FA-7C42-4720-811F-F33855E02042Q35593356-F4E4A6DB-A47B-432E-B83B-91885B9A26C4Q35867912-7F38D735-333B-4AFA-B82B-F2D49366F43CQ36072569-AED300D9-ED9B-4D02-B5DB-F1D82138C19CQ36126937-46A3B430-680D-4C85-A0E2-2A676BD68A7BQ36289608-D05FF476-C3AB-4E89-ACCD-29C1534054B4Q36706902-19AA3C98-098C-474E-81E5-7C3A544AC661Q36744386-B3828E0B-B166-4621-BBB3-106EF4887075Q36862527-A2D5F998-717F-48BD-A657-B5B2540E8908Q37054486-CF25B073-4F26-4BEC-A249-F021F3DD1A01Q37206855-612EB178-0946-444C-B310-BDD678B464FFQ37262777-BF34688B-4D0A-48AA-B47C-31BB69E927A2Q37328427-9D418BB6-B08B-472C-98DA-3675F289A2F9Q37394305-1354369C-60A2-4D65-8CF3-2357412BE687Q37395438-6DDD8B7D-690E-4876-9868-B34C6FDB94D7Q37627491-275B8B7A-E44A-48C2-B07E-A470B5DF7E48Q37763239-5A29B9B9-DAD4-4B0C-AED9-AE33706CA895Q37766197-8C6B2FE9-3C8E-49C3-A81C-B77F187A9EC1Q37884379-03679E0B-A772-4A53-A951-3A94107319BEQ38005087-3B033C01-CB56-4DBD-B0B5-CF1160F72E34Q38131049-9F35A9ED-684F-4C3C-9EE1-C8266F1B3495Q38244397-DC4480A6-6A0C-4A52-9441-EB426FB7C62BQ38302018-D82E9A05-5E33-4B62-9E1B-E886B0E6FAF5Q38303827-743386E6-1047-42AC-A208-973A73963200Q38316150-ECF3B03F-FA05-4A6A-B525-978C8816FD13Q38345295-EC13F358-7634-436E-A43F-D278459C5BB4Q38345353-C45BCA46-31BF-455D-8EFB-A35F0523E998
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Andrew Zannettino
@ast
Andrew Zannettino
@en
Andrew Zannettino
@es
Andrew Zannettino
@nl
type
label
Andrew Zannettino
@ast
Andrew Zannettino
@en
Andrew Zannettino
@es
Andrew Zannettino
@nl
prefLabel
Andrew Zannettino
@ast
Andrew Zannettino
@en
Andrew Zannettino
@es
Andrew Zannettino
@nl
P106
P1153
6603809529
P31
P496
0000-0002-6646-6167